pentobarbital will lessen the level or impact of roflumilast by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not encouraged; robust cytochrome P450 enzyme inducers reduce systemic publicity to roflumilast and will reduce the therapeutic effectivenesspentobarbital will minimize the extent or influence of